| Synta Pharmaceuticals resented new data on the mechanism of action of elesclomol, a first-in-class oxidative stress inducer, at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston, MA. “Elesclomol has been shown previously to induce apoptosis in cancer cells by increasing the level of reactive oxygen species,” said Vojo Vukovic M.D., Ph.D., Chief Medical Officer, Synta Pharmaceuticals. :theflyonthewall.com |
Subscribe for More Information